Browse

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”